Clinical Trials for Kidney Cancer & Sporadic Renal AMLs

  • Clinical trials play an important role in advancing scientific knowledge and helping shape the care of future cancer patients. “Through clinical trials, we acknowledge the limitations of current care and advance care through discovery.” said Robert Uzzo, MD, FACS, Chair of the Department of Surgical Oncology at Fox Chase Cancer Center. “Our urological oncologists strive to provide best standards of care and clinical trials serve as meaningful contributions to this care.”

    Dr. Uzzo serves as President of the Society of Urologic Oncology Clinical Trials Consortium which oversees all clinical trials for the SUO.  He has served as Principle Investigator or Co-PI in multiple national and international trials in Urologic Oncology as well as on multiple data safety monitoring boards. He currently serves as PI on two clinical research studies that are actively recruiting patients.

    One study uses Atezolizumab as adjuvant therapy in participants with renal cell carcinoma. This is the first and largest adjuvant kidney cancer trial to date assessing the role of checkpoint inhibitors to prevent recurrence.

    The purpose of the second research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells. Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.

    Choosing to participate in a clinical trial is an important decision. If you would like more information about this clinical trial or other clinical trials at Fox Chase Cancer Center, call 215-214-1515 during normal business hours or fill out this form.


Updates in Urologic Oncology